NCT07461454RecruitingPhase 3
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
A Randomized, Open-label, Multicenter, Phase 3 Study of YL202 Versus Treatment of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy
Source: ClinicalTrials.gov · Last updated 26 May 2026
Brief summary (registry, in English)
The study will evaluate the safety and efficacy of YL202, when compared with treatment of physician's choice (eribulin, capecitabine, vinorelbine, gemcitabine or sacituzumab govitecan) in participants with unresectable locally advanced, recurrent or metastatic hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer who had failed at least one line of chemotherapy.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 376 (estimated)
- First submitted
- 4 Mar 2026
- Start date
- 17 Mar 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Diseases
- Metastatic breast cancer
- NCT number
- NCT07461454
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 376
- From 17 Mar 2026 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have prior treatment with an agent targeting HER3.
- Have prior treatment with topoisomerase I inhibitor or an ADC that consists of topoisomerase I inhibitor.
- Have insufficient washout period for prior anticancer therapy prior to first dose of the study drug.
- Have major surgery (excluding diagnostic surgery) within 4 weeks prior to the first dose of study drug or anticipation of major surgery during the study.
- Have clinically significant concomitant pulmonary diseases.
- Have serious infection within 4 weeks prior to the first dose.
Other illness
- Have uncontrolled or clinically significant cardiovascular and cerebrovascular disease.
- Have a history of severe hypersensitivity reactions to the drug substance, inactive ingredients in the drug product, or other monoclonal antibodies.
Other
- Leptomeningeal metastases or carcinomatous meningitis, spinal cord compression.
- Have uncontrolled pleural effusion, abdominal effusion.
Who the study is looking for
- Have been informed of the study before the start of the study and voluntarily sign name and date on the informed consent form.
- Histologically and/or cytologically confirmed locally advanced or metastatic HR+/HER2- breast cancer who are not candidates for curative surgery or radiotherapy.
- Patients who had failed at least one line of systemic chemotherapy in unresectable locally advanced, recurrent, or metastatic stage.
- Have at least 1 extracranial measurable lesion as a target lesion per RECIST 1.1.
- Tumor tissue samples can be provided at the time of diagnosis of locally advanced or metastatic tumors.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
- Have Adequate organ and bone marrow function within 7 days prior to the first dose.
- Female patients of childbearing potential must agree to use highly effective contraception from screening throughout the duration of the study and for at least 6 months after the last dose of study drug.
- Have a expected survival ≥ 3 months.
- Have ability and willingness to comply with protocol-specified visits and procedures.
Age in the registry: 18 years to 75 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.